Literature DB >> 21487763

Comparison of culture media for detection of Acinetobacter baumannii in surveillance cultures of critically-ill patients.

A O Ajao1, G Robinson, M S Lee, T D Ranke, R A Venezia, J P Furuno, A D Harris, J K Johnson.   

Abstract

The objective of this study was to evaluate the performance of CHROMagar Acinetobacter when compared to sheep blood agar, MacConkey agar and MacConkey agar with 6 μg/ml of imipenem for the detection of A. baumannii in surveillance cultures of hospitalized patients. We utilized peri-anal swabs and sputum samples from patients admitted to the University of Maryland Medical Center ICUs from December 7 through December 21, 2009. Samples were plated onto four media in the following order: (1) 5% sheep blood agar (SBA), (2) MacConkey agar, (3) MacConkey agar with 6 μg/ml of imipenem, and (4) CHROMagar Acinetobacter (CHROMagar). SBA was the gold standard to which all media was compared. There were 165 samples collected during the study period. SBA and CHROMagar detected 18 of 18 (100%) Acinetobacter and 11 of 11 (100%) MDR-A. baumannii. MacConkey agar detected 16 of 18 (89%) Acinetobacter and 10 of 11 (91%) MDR- A. baumannii while MacConkey agar with 6 μg/ml imipenem detected 9 of 11 (82%) MDR-A. baumannii. CHROMagar did not differentiate MDR- A. baumannii from non-MDR-A. baumannii. CHROMagar may be useful for rapid detection of patients with MDR-A. baumannii if improved upon to better select for MDR-A. baumannii.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21487763      PMCID: PMC3660032          DOI: 10.1007/s10096-011-1237-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  26 in total

1.  Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40.

Authors:  Karen Lolans; Thomas W Rice; L Silvia Munoz-Price; John P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  An outbreak of multidrug-resistant Acinetobacter baumannii associated with pulsatile lavage wound treatment.

Authors:  Lisa L Maragakis; Sara E Cosgrove; Xiaoyan Song; Denny Kim; Patricia Rosenbaum; Nancy Ciesla; Arjun Srinivasan; Tracy Ross; Karen Carroll; Trish M Perl
Journal:  JAMA       Date:  2004-12-22       Impact factor: 56.272

3.  Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences.

Authors:  E G Playford; J C Craig; J R Iredell
Journal:  J Hosp Infect       Date:  2007-01-23       Impact factor: 3.926

4.  Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia.

Authors:  Ki Tae Kwon; Won Sup Oh; Jae-Hoon Song; Hyun-Ha Chang; Sook-In Jung; Shin-Woo Kim; Seong Yeol Ryu; Sang Taek Heo; Dong Sik Jung; Ji-Young Rhee; Sang Yop Shin; Kwan Soo Ko; Kyong Ran Peck; Nam Yong Lee
Journal:  J Antimicrob Chemother       Date:  2007-01-09       Impact factor: 5.790

5.  Multicenter evaluation of BBL CHROMagar MRSA medium for direct detection of methicillin-resistant Staphylococcus aureus from surveillance cultures of the anterior nares.

Authors:  Diane Flayhart; Janet F Hindler; David A Bruckner; Geraldine Hall; Rabin K Shrestha; Sherilynn A Vogel; Sandra S Richter; Wanita Howard; Rhonda Walther; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

6.  Identification of TEM-26 beta-lactamase responsible for a major outbreak of ceftazidime-resistant Klebsiella pneumoniae.

Authors:  C Urban; K S Meyer; N Mariano; J J Rahal; R Flamm; B A Rasmussen; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

7.  Description of Leeds Acinetobacter Medium, a new selective and differential medium for isolation of clinically important Acinetobacter spp., and comparison with Herellea agar and Holton's agar.

Authors:  A Jawad; P M Hawkey; J Heritage; A M Snelling
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

8.  A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenem-hydrolysing oxacillinase OXA-58.

Authors:  Claire Héritier; Anne Dubouix; Laurent Poirel; Nicole Marty; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2004-12-08       Impact factor: 5.790

9.  Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization.

Authors:  Rebecca H Sunenshine; Marc-Oliver Wright; Lisa L Maragakis; Anthony D Harris; Xiaoyan Song; Joan Hebden; Sara E Cosgrove; Ashley Anderson; Jennifer Carnell; Daniel B Jernigan; David G Kleinbaum; Trish M Perl; Harold C Standiford; Arjun Srinivasan
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

10.  Epidemiological surveillance of Acinetobacter species.

Authors:  K A Wise; F A Tosolini
Journal:  J Hosp Infect       Date:  1990-11       Impact factor: 3.926

View more
  9 in total

1.  Use of fluoroquinolones is the single most important risk factor for the high bacterial load in patients with nasal and gastrointestinal colonization by multidrug-resistant Acinetobacter baumannii.

Authors:  V C C Cheng; J H K Chen; S Y C So; S C Y Wong; M K Yan; P H Chau; W M Lee; K K W To; J F W Chan; I F N Hung; P L Ho; K Y Yuen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-09-15       Impact factor: 3.267

2.  Laboratory evaluation of different agar media for isolation of carbapenem-resistant Acinetobacter spp.

Authors:  J Moran-Gilad; A Adler; D Schwartz; S Navon-Venezia; Y Carmeli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-28       Impact factor: 3.267

3.  Infrequent air contamination with Acinetobacter baumannii of air surrounding known colonized or infected patients.

Authors:  Clare Rock; Anthony D Harris; J Kristie Johnson; Werner E Bischoff; Kerri A Thom
Journal:  Infect Control Hosp Epidemiol       Date:  2015-03-31       Impact factor: 3.254

4.  Task force on management and prevention of Acinetobacter baumannii infections in the ICU.

Authors:  José Garnacho-Montero; George Dimopoulos; Garyphallia Poulakou; Murat Akova; José Miguel Cisneros; Jan De Waele; Nicola Petrosillo; Harald Seifert; Jean François Timsit; Jordi Vila; Jean-Ralph Zahar; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2015-10-05       Impact factor: 17.440

5.  Failure to Communicate: Transmission of Extensively Drug-Resistant bla OXA-237-Containing Acinetobacter baumannii-Multiple Facilities in Oregon, 2012-2014.

Authors:  Genevieve L Buser; P Maureen Cassidy; Margaret C Cunningham; Susan Rudin; Andrea M Hujer; Robert Vega; Jon P Furuno; Steven H Marshall; Paul G Higgins; Michael R Jacobs; Meredith S Wright; Mark D Adams; Robert A Bonomo; Christopher D Pfeiffer; Zintars G Beldavs
Journal:  Infect Control Hosp Epidemiol       Date:  2017-09-05       Impact factor: 3.254

6.  Comparison of swab and sponge methodologies for identification of Acinetobacter baumannii from the hospital environment.

Authors:  Kerri A Thom; Tracy Howard; Sophie Sembajwe; Anthony D Harris; Paula Strassle; Brian S Caffo; Karen C Carroll; J Kristie Johnson
Journal:  J Clin Microbiol       Date:  2012-03-29       Impact factor: 5.948

7.  Assessing the burden of Acinetobacter baumannii in Maryland: a statewide cross-sectional period prevalence survey.

Authors:  Kerri A Thom; Lisa L Maragakis; Katie Richards; J Kristie Johnson; Brenda Roup; Patricia Lawson; Anthony D Harris; Elizabeth P Fuss; Margaret A Pass; David Blythe; Eli N Perencevich; Lucy Wilson
Journal:  Infect Control Hosp Epidemiol       Date:  2012-07-23       Impact factor: 3.254

8.  Modified CHROMagar Acinetobacter medium for direct detection of multidrug-resistant Acinetobacter strains in nasal and rectal swab samples.

Authors:  Wonkeun Song; Jacob Lee; Taek-Kyung Kim; Min-Jeong Park; Han-Sung Kim; Jae-Seok Kim
Journal:  Ann Lab Med       Date:  2013-04-17       Impact factor: 3.464

9.  Rapid identification of nosocomial Acinetobacter baumannii isolated from a surgical intensive care unit in Egypt.

Authors:  Doaa Mohammad Ghaith; Reem Mostafa Hassan; Ahmed Mohamed Hasanin
Journal:  Ann Saudi Med       Date:  2015 Nov-Dec       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.